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Background: Intranasal corticosteroids are known to improve the symptoms
of rhinosinusitis. However, in acute rhinosinusitis, the efficacy of intranasal
corticosteroid used with oral antibiotics still needs further evidence.
Aim of Work: The aim of this study was to clinically compare the efficacy of
topical corticosteroid and oral antibiotic combination therapy versus the use of
oral antibiotic alone when treating acute rhinosinusitis regarding main symptoms
(nasal obstruction, purulent nasal discharge, anosmia and facial pain), and also
evaluating congestion and edema of middle meatus by using nasal endoscopy.
Materials and Methods: One hundred patients diagnosed with acute
rhinosinusitis were divided into two groups. Group A received a combination of
oral antibiotic (amoxicillin clavulanic acid) 50mg/kg/day for 10 days and local
steroid spray (mometasone furoate) 2 sprays (50 mcg of mometasone furoate
in each spray) in each nostril once daily for 10 days, while group B, the control
group, received the oral antibiotic alone. Follow-up was after 10 days with SinoNasal Outcome test questionnaire and nasal endoscopy. A comparison between
both groups regarding major nasal symptoms and endoscopic findings was done.
Results: Group A showed superior results than group B, which received antibiotics
alone, regarding the obstructive symptoms. There were statistical significant
differences between both groups regarding nasal obstruction, hyposmia, facial
pain, nasal congestion and edema at the middle meatus with p values 0.012,
0.013, < 0.001, and 0.006 respectively. There was no significant difference
between the two groups as regards the purulent nasal discharge.
Conclusion: Intranasal corticosteroid spray in ABR is very useful when used beside
oral antibiotics despite the minimal side effects reported. This showed a great
effect in relieving obstructive symptoms and signs including nasal obstruction,
hyposmia, facial pain, nasal congestion and edema at the middle turbinate.
Keywords: Acute rhinosinusitis,
corticosteroid, mometasone furoate.
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Introduction
Rhinosinusitis is one of the most common conditions
for which patients seek medical care. It can be defined
according to the European Position Paper on Rhinosinusitis
and Nasal Polyps (EPOS) as inflammation of the nose and the
paranasal sinuses characterised by two or more symptoms,
one of which should be either nasal blockage/obstruction/
congestion or nasal discharge (anterior/posterior nasal drip),
and maybe facial pain/pressure, or reduction/ loss of smell.
Definition also entails endoscopic signs of nasal polyps, and/
or mucopurulent discharge primarily from middle meatus,
and/or oedema/mucosal obstruction primarily in the middle
meatus and/or CT findings of mucosal changes with the
ostiomeatal complex (OMC) and/or sinuses. [1]
Acute rhinosinusitis (ARS) is defined as rhinosinusitis lasting
up to four weeks. Viruses cause most ARS but discriminating
between viral and bacterial rhinosinusitis is challenging and
impossible in daily practice. [2] Factors suggesting acute
bacterial rhinosinusitis (ABRS) entails worsening of the
symptoms after five days, or the persistence of symptoms
for more than 10 days, or the presence of symptoms out
of proportion to those typically associated with upper viral
respiratory tract infections. [3]
For assessment of the severity of rhinosinusitis, the EPOS

has formulated the question “How troublesome are your
symptoms of rhinosinusitis?” and the patient is given a visual
analogue scale (VAS) from 1 to 10, and according to his/her
answer the severity of rhinosinusitis can be assessed, where
0-3 score is considered mild, >3-7 is considered moderate,
and >7-10 score is severe. It was found that VAS score >5
affects the patient quality of life. [2]
The initial treatment for ARS is always medical. The majority
of patients seen in primary care for acute sinusitis are
prescribed antibiotics, despite evidence that they provide
limited benefit. The effectiveness of other treatments such
as decongestants and antihistamines is largely unknown.
[4] Antibiotics are effective in patients with ARS only in
cases involving bacterial origin. Expert consensus guidelines
recommend antibiotics only for patients with severe
symptoms persisting for 10 days or more or for worsening
of symptoms after initial improvement. [5] One group of
authors concluded that ARS resolves without antibiotic
treatment, [6] while another group found that the overall
efficacy of antibiotics is moderate. [7]
The recommended length of antibiotic therapy is 10 days,
however, a shorter treat¬ment course of three to five
days may be just as effective and is associated with fewer
adverse effects. [8] The incidence of b-lactamase production
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of H. influenza, and M. catarrhalis is around 40 and 90%,
respectively. Thus, antibiotics that cover b-lactamase
producing bacteria are reasonable choices if initial antibiotics,
such as amoxicillin, trimethoprim–sulfamethoxazole or
doxycycline fail to improve symptoms. [9]
Corticosteroids have a profound effect on the inflammatory
response and suppress many elements of the allergic
inflammatory cascade. They reduce eosinophil infiltration
and suppress cytokines, dramatically reducing the infiltration
of inflammatory cells into the nasal mucosa. Corticosteroids
also reduce the release of histamine and leukotrienes,
though this may be due to a reduction in the overall number
of inflammatory cells in the epithelium. [10] In patients
with recurring acute rhinosinusitis, The Steroid nasal sprays
(SNSs) have been shown to improve the global symptoms of
acute episodes, especially those related to “obstruction” such
as headache, congestion, and facial pain. [11]
The steroid nasal sprays (SNSs) without antibiotic showed a
greater improvement in total and major symptoms than the
antibiotic alone, raising the question of the relative importance
of antimicrobial as compared to anti-inflammatory treatment.
Intranasal corticosteroids used with antibiotics showed
improvement in ARS symptoms compared with antibiotic
therapy alone. [12]
Although the efficacy and safety of intranasal corticosteroids
(INCs) are well established for the management of allergic
rhinitis, rhinosinusitis, and nasal polyps, concerns remain that
these agents may reach the systemic circulation in sufficient
concentration to produce adverse effects. [13] There are two
aspects of absorption regarding the Intranasal spray (INS).
One is topical absorption at the target site that determines
therapeutic efficacy and the other is systemic absorption.
Systemic absorption either occurs from the fraction of
INS swallowed and subsequently absorbed through the
gastrointestinal tract or from the fraction absorbed into the
blood at the nasal mucosa. [14]
The reported side effects of intranasal corticosteroids are
epistaxis, nasal burning and irritation, and a dry nose. These
are usually well tolerated, and the benefit of treatment clearly
outweighs the associated risks. [15]
The aim of this study was to clinically compare the efficacy
of topical corticosteroid and oral antibiotic combination
therapy versus the use of oral antibiotic alone when treating
acute rhinosinusitis regarding main symptoms of acute
rhino sinusitis (nasal obstruction, purulent nasal discharge,
anosmia and facial pain), and also evaluating congestion and
edema of middle meatus by using nasal endoscopy.
Materials and Methods
One hundred patients were selected from ENT clinic during
the period from January 2016 till December 2016 at Kasr
Alainy hospital, Cairo, Egypt. Their ages ranged between
(18-55) years old and were diagnosed as acute rhinosinusitis
by the presence of two or more major signs or one major and
two minor signs of acute rhinosinusitis. Major signs included
facial pain/pressure/fullness, nasal obstruction/blockage,
nasal/postnasal discharge/Purulence (either by history or by
examination), hyposmia/anosmia, and/or fever. While minor
sings included headache, fatigue, dental pain, cough, and/or
ear pain/pressure/fullness.
Patients were divided into two groups. Group A received a
combination of oral antibiotic (amoxicillin clavulanic acid)
50mg/kg/day for 10 days and local steroid spray (mometasone
furoate) 2 sprays (50 mcg of mometasone furoate in each
spray) in each nostril once daily for 10 days, while group B,
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the control group, received oral antibiotic alone (amoxicillin
clavulanic acid) 50mg/kg/day for 10 days. Nasal endoscopy
was used to assess different signs at day 0 and at end of day
10. Exclusion criteria included patients with complicated ARS,
patients who had chronic or allergic rhinosinusitis, patients
who were hypersensitive to amoxicillin clavulanic acid and/
or patients who had ARS on top of neoplastic lesions in the
nose and paranasal sinuses. Patients were then examined
by 0-degree nasal endoscope before and after treatment
to assess degree of congestion, edema, and purulent nasal
discharge at middle meatus.
All patients were asked to complete a questionnaire assessing
their nasal symptoms at day 0 and at the end of day 10 using
Sino-Nasal Outcome test (SNOT-22).
Data were coded and entered using the statistical package
SPSS version 23. Data was summarized using mean and
standard deviation for quantitative variables and frequencies
(number of cases) and relative frequencies (percentages)
for categorical variables. Comparisons between quantitative
variables in the 2 groups were done using unpaired t test.
For comparing categorical data, Chi square ((Ҳ2) test was
performed. Exact test was used instead when the expected
frequency is less than 5. P-values less than 0.05 were
considered as statistically significant.
Results
The age in this study ranged from 18 till 55 years in the two
groups with mean value 34.78±9.77 in group A, and mean
value 32.94±9.79 in group B, with insignificant difference
between the two groups (p value 0.349). This study included
57 males representing 57 % of the total cases and 43 females
representing 43 %, with 28 males (56%) and 22 females
(44%) in group A and 29 males(58%) and 21 females (42%)
in group B.
Results of comparison between both groups were
summarized in Table 1. Regarding Nasal obstruction, there
was a statistically significant difference between patients in
the two groups at the end of day 10 with (p value 0.012).
Patients with no nasal obstruction post treatment in group
A were 28 (56%) while in group B were 14 (28%). There
was only one patient (2%) with sever nasal obstruction post
treatment in group A, while there were 6 patients in group B
(12%). were 0 (0%) while in group B were 0 (0%).
There was no statistically significant difference in purulent
nasal discharge between patients in the two groups at the
end of day 10 with (p value 0.901). Patients with no purulent
discharge post treatment in group A were 32 (64%) while
there were 31 (62%) in group B. There were no patients
with purulent nasal discharge post treatment in both groups.
As for hyposmia, there was a statistically significant difference
between patients in the two groups at the end of day 10 with
(p value 0.013). Patients with no hyposmia post treatment
in group A were 38 (78%) while in group B were 31 (62%).
In group A, there was only one patient (2%) showed
moderate hyposmia while there were no patients with severe
hyposmia. While in group B, patients with moderate and
severe hyposmia post treatment were 11 (10 moderate and
1 severe). There was a statistically significant difference in
the facial pain between patients in the two groups at the
end of day 10 with (p value < 0.001). Patients with no facial
pain post treatment were 24 (48%) in group A, while in
group B were 9 (18%). Only one patient complaint of severe
facial pain post treatment in group A (2%), while in group B
thirteen had this symptom post treatment (26%).
Regarding congestion and edema at the middle meatus,
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there was a statically significant difference between patients
in the two groups at the end of day 10 with (p value 0.006).
Patients showed no obstruction post treatment in group A

were 39 (78%) and 20 (40%) in group B. patients. There
were 5 patients (10%) with complete obstruction in group B,
while there was none in group A.

Table 1 Comparison between group A and group B regarding nasal obstruction, hyposmia, facial pain, purulent nasal
discharge, and congestion/edema at middle turbinate
Post treatment
Group A

Nasal obstruction

Hyposmia

Facial pain

Purulent nasal discharge

Congestion and edema
at middle meatus

Group B

Count

%

Count

%

No

28

56.0%

14

28.0%

Mild

11

22.0%

20

40.0%

Moderate

10

20.0%

10

20.0%

Severe

1

2.0%

6

12.0%

No

38

76.0%

31

62.0%

Mild

11

22.0%

8

16.0%

Moderate

1

2.0%

10

20.0%

Severe

0

0.0%

1

2.0%

No

24

48.00%

9

18.00%

Mild

15

30.00%

5

10.00%

Moderate

4

8.00%

14

28.00%

Severe

1

2.00%

13

26.00%

No

32

64.0%

31

62.0%

Mild

14

28.0%

16

32.0%

Moderate

4

8.0%

3

6.0%

Severe

0

.0%

0

.0%

No obstruction

39

78.0%

20

40.0%

Partial obstruction and
edema

11

22.0%

24

48.0%

Complete obstruction and
edema

0

.0%

5

10.0%

Discussion
Sinusitis or rhinosinusitis is inflammation of the paranasal
sinuses. It can be due to infection, allergy, or autoimmune
issues. It is a common condition in medical practice, which
affects many people worldwide and its prevalence is rising.
[16]
In this study, we compared patients who were diagnosed
with ABR and treated with topical corticosteroid and oral
antibiotics (group A) with those treated with oral antibiotics
alone (group B).
Patients in group A who received topical nasal corticosteroid
spray with oral antibiotics showed greater improvement
regarding most of the major symptoms of acute rhinosinusitis
(nasal obstruction, hyposmia, and facial pain) than patients
in group B who received oral antibiotics alone, although
there was no statistically significant difference as regarding
purulent nasal discharge.

P value

0.012

0.013

< 0.001

0.901

0.006

The majority of patients seen in primary care for acute sinusitis
are prescribed antibiotics, despite evidence that they provide
limited benefit. [4] Although most cases of rhinosinusitis
are of viral origin, still the use of antibiotics is preferred.
Prevention of complications of bacterial rhinosinusitis, such as
meningitis, orbital or intracranial complications, is sometimes
mentioned as a reason for antibiotic treatment. [17]
In our study, patients in both group received oral antibiotic
in the form of amoxicillin clavulanic acid as the first line
antibiotic for acute bacterial rhinosinusitis related to its
safety, efficacy, low cost, and narrow microbiologic spectrum.
Patients known to have allergy from penicillin were excluded
from the study. Karageorgopoulos et al (2008) , showed that
newer fluoroqui¬nolones conferred no benefit over betalactam antibiot¬ics and are not recommended as first-line
agents. [18]
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In the current study, intranasal corticosteroid spray was used
by patients in group A. Intranasal corticosteroid spray was
used to facilitate drainage and reduce mucosal swelling of
inflamed tissues. [19]
Similar to this study, Meltzer et al. (2000) showed a high
degree of agreement with our results. In their study,
antibiotics were prescribed in addition to mometasone
furoate nasal corticosteroids spray or placebo and it showed
that adjunctive treatment with corticosteroid spray caused a
significantly greater decrease in total symptom score and in
individual scores of inflammatory symptoms associated with
the obstruction process (headache, congestion, and facial
pain) compared with placebo. Symptoms associated with the
secretory processes were improved to a lesser degree. [11]
The absence of a significant difference between patients in
the two groups regarding purulent nasal discharge can be
explained as patients in both group have received the same
type of antibiotic for the same period of time leading to same
improvement in both groups.
As our results, Nayak et al., 2002 in their study showed the
relative safety and efficacy of INCSs in providing modest
symptom relief in patients with ABRS, patients treated
with amoxicillin clavulanate were randomized to receive
mometasone furoate nasal spray (MFNS) 400 mg twice daily
or placebo. Data indicated that the inflammatory symptoms
of headache, nasal congestion, and facial pain were
significantly reduced with MFNS adjunctive therapy versus
placebo. The rationale for intranasal corticosteroids in acute
rhinosinusitis resides in their anti-inflammatory properties, as
inflammation and edema of the mucous membrane of the
nasal turbinates and sinus ostia block the drainage routes
and impair mucociliary clearance mechanisms, so reducing
inflammation by using intranasal corticosteroids leads to
faster drainage, increased aeration and better access for
antibiotics. [20]
This can give a good explanation for the improvement of
nasal obstruction in patients of group A more than patients in
group B as nasal obstruction in acute rhinosinusitis is known
to be because of the stagnation of the secretions due to the
impaired function of the mucociliary clearance mechanism
thus leading to nasal obstruction and also creating a media
for bacterial growth. Anosmia/Hyposmia improvement in
group A more than in group B can also be explained as nasal
obstruction, edema and congestion of nasal mucosa are
known to be one of the most important cause of temporarily
loss of smell.
Fokkens et al., 2007 recommended the use of intranasal
corticosteroids (INCS)–but not antibiotics–as a first step in
treatment. In mild to moderate severity illness, antibiotics
are reserved for patients who fail to respond to INCS after
3 days and whose symptoms continue for more than 7
days. For patients presenting with severe illness, INCS and
antibiotics are recommended in combination as a first step in
treatment. [1]
In contrast to our study, Williamson et al ., 2007 found
that antibiotics and intranasal corticosteroids, alone or in
combination, were ineffective. This study suggested that
intranasal corticosteroids may be effective in patients with
less severe symptoms at baseline. [21] In a meta-analysis
which included 6 studies having a total of 2,495 patients,
5 studies of which antibiotics were prescribed in addition to
corticosteroids or placebo. This meta-analysis concluded that
Intranasal corticosteroids offer a small therapeutic benefit in
acute sinusitis, which may be greater with high doses and
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with courses of 21 days’ duration. [22]
On the other hand, the use of intranasal corticosteroid spray
is safe which is confirmed by (Giger et al., 2003) study. In a
randomized, double-blind, parallel-group trial involving 112
patients with non-allergic chronic rhinosinusitis, they did
not detect any signs of adrenal suppression or significant
changes in morning serum cortisol values with once- or
twice-daily intranasal beclometasone dipropionate (400 μg/
day) administered for 12 weeks. [23]
In our study, the most frequently reported adverse effects
from the treatment in both group A and group B were
diarrhea and nausea/vomiting, for which the given antibiotic
was blamed more than a side effect of the INCS which was
given only to group A and only a small number of patients
withdrew from the study by stopping taking the medication.
In this study, patients with recurrent acute rhinosinusitis,
which is defined by symptoms and physical findings consistent
with acute rhinosinusitis, with these symptoms and findings
worsening after five days or when persisting more than 10
days there, were found to be 10 patients in both group (10%)
with 4 patients in group A (40%) and 6 patients in group B
(60%). While patients who fail to respond to treatment in
both groups and presented with persistent sever symptoms
were 7 patients regarding nasal obstruction (7%), 1 patient
regarding anosmia (1%) , 14 patients regarding facial pain
(14%) and 5 patients regarding congestion at middle meatus
(5%).
Conclusion
It was concluded that the use of intranasal corticosteroid
spray in ABR is very useful when used beside oral antibiotics
despite the minimal side effects reported. This showed a great
effect in relieving symptoms especially those related to nasal
obstruction, hyposmia, and facial pain. It also showed a great
effect on congestion and edema at the middle meatus which
helps in quick improvement of patients’ symptoms. However,
regarding the purulent nasal discharge, there was no great
difference in patients treated with oral antibiotics alone and
patients treated with combination of oral antibiotics and
intranasal corticosteroids.
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